Flemming Ørnskov, Galderma CEO

Gal­der­ma drug pass­es PhI­II in rare skin dis­ease, set­ting the stage for ap­proval re­quest

Der­ma­tol­ogy be­he­moth Gal­der­ma is one step clos­er to reg­u­la­tors’ doorsteps for a mon­o­clon­al an­ti­body it li­censed from Chugai Phar­ma­ceu­ti­cal af­ter a Phase III read­out Wednes­day.

The for­mer Nestlé Skin Health unit said that the drug, named nemolizum­ab, passed muster in one of two Phase III tri­als in the rare skin dis­ease pruri­go nodu­laris. The drug, test­ed on its own, was able to clear most skin le­sions and re­duce itch­ing in pa­tients with the rare skin dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.